Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Kinase Assay from US Patent US20240199649: "4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF"
Assay data:158 Active, 42 Activity ≤ 1 nM, 157 Activity ≤ 1 µM, 158 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
ADP-Glo Assay Promega from US Patent US20240199561: "INHIBITORS OF DYRK AND PIM"
Assay data:17 Active, 17 Activity ≤ 1 µM, 17 Tested
DYRK1A SGC Tm panel (DSF)
Assay data:1 Tested
SummaryRelated BioAssays by Target
CLK1 SGC Tm panel (DSF)
CLK3 SGC Tm panel (DSF)
CLK1 Invitrogen Lab (UK) kinase screen (BI)
Inhibition of recombinant human GST-tagged DYRK1A expressed in Escherichia coli using Woodtide as substrate in presence of [gamma-33P] ATP incubated for 30 mins by scintillation counter analysis
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of CLK2 (unknown origin) at 1 uM relative to control
Assay data:3 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of CLK1 (unknown origin) at 1 uM relative to control
Inhibition of wild type human DYRK1A in presence of ATP by radiometric kinase assay
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on